<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pericardial disease associated with cancer: Management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pericardial disease associated with cancer: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pericardial disease associated with cancer: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barry A Borlaug, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Malcolm M DeCamp, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin M LeWinter, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H602084117"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cancer commonly involves the pericardium, with clinical presentations ranging from acute syndromes to more indolent conditions.</p><p>The management of pericardial disease associated with cancer is reviewed here. The clinical presentation and diagnosis of pericardial disease associated with cancer is presented separately. (See  <a class="medical medical_review" href="/d/html/4954.html" rel="external">"Pericardial disease associated with cancer: Clinical presentation and diagnosis"</a>.)</p><p class="headingAnchor" id="H401959944"><span class="h1">GENERAL APPROACH</span><span class="headingEndMark"> — </span>The management of pericardial disease in a patient with cancer is based upon multiple factors, including (see  <a class="medical medical_review" href="/d/html/4954.html" rel="external">"Pericardial disease associated with cancer: Clinical presentation and diagnosis"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms and hemodynamic status</p><p class="bulletIndent1"><span class="glyph">●</span>Type of pericardial disease (eg, pericardial effusion with or without cardiac tamponade, acute pericarditis, constrictive pericarditis)</p><p class="bulletIndent1"><span class="glyph">●</span>Etiology of the pericardial disease (eg, malignancy, cancer therapy, infection, or other conditions)</p><p class="bulletIndent1"><span class="glyph">●</span>The type and stage of the cancer, with available treatments</p><p class="bulletIndent1"><span class="glyph">●</span>Cancer prognosis, patient comorbidities, performance status, and goals of care (see  <a class="medical medical_review" href="/d/html/95552.html" rel="external">"Discussing goals of care"</a>)</p><p></p><p>Of note, some patients with malignant pericardial disease may not be appropriate candidates for aggressive therapy due to poor performance status, poor cancer prognosis, and/or multiple comorbidities. Patients who opt for best supportive care alone are not candidates for the treatment approaches discussed in this topic. Palliative care for patients at end of life is discussed separately. (See  <a class="medical medical_review" href="/d/html/14241.html" rel="external">"Palliative care: The last hours and days of life"</a>.)</p><p class="headingAnchor" id="H2822366021"><span class="h1">ACUTE MANAGEMENT OF CARDIAC TAMPONADE</span><span class="headingEndMark"> — </span>For patients with cancer with clinical evidence of cardiac tamponade, the approach to acute management is similar to that for the general population  (<a class="graphic graphic_algorithm graphicRef119617" href="/d/graphic/119617.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis"</a>.)</p><p>Management details relevant to patients with cancer are as follows:</p><p class="headingAnchor" id="H2946563191"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Volume repletion is imperative while preparing for pericardial fluid drainage. Inotropic support is rarely indicated. Positive pressure mechanical ventilation should be avoided, if possible. Further details on supportive care for cardiac tamponade are discussed separately. (See  <a class="medical medical_review" href="/d/html/4921.html" rel="external">"Cardiac tamponade", section on 'Supportive care'</a> and  <a class="medical medical_review" href="/d/html/4921.html" rel="external">"Cardiac tamponade", section on 'Treatment of the underlying condition'</a>.)</p><p class="headingAnchor" id="H310368422"><span class="h2">Patients on anticoagulation</span><span class="headingEndMark"> — </span>Patients with cancer may also concurrently be anticoagulated for other clinical conditions, such as venous thromboembolism, which must be addressed prior to performing pericardial fluid drainage. The approach to pericardiocentesis in patients on anticoagulation or bleeding/clotting disorders is discussed separately. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis"</a>.)</p><p class="headingAnchor" id="H2047406438"><span class="h2">Urgent drainage</span><span class="headingEndMark"> — </span>For patients with cancer and cardiac tamponade, urgent pericardial fluid removal is required for therapeutic and diagnostic purposes. Removal of pericardial fluid is necessary to alleviate symptoms and prevent hemodynamic collapse. This approach generally results in rapid and dramatic improvement in symptoms and hemodynamics. Pericardial fluid or tissue sampling is also necessary to confirm the diagnosis of malignant pericardial effusion and, if indicated, to direct subsequent antineoplastic therapy once the patient is hemodynamically stable. (See  <a class="medical medical_review" href="/d/html/4954.html" rel="external">"Pericardial disease associated with cancer: Clinical presentation and diagnosis", section on 'Diagnosis of malignant pericardial disease'</a> and <a class="local">'Cancer-directed therapy'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedure for initial acute pericardial fluid removal</strong> – Pericardial fluid is typically removed percutaneously (ie, using pericardiocentesis under echocardiographic guidance) or surgically (ie, using a pericardial window)  (<a class="graphic graphic_algorithm graphicRef119617" href="/d/graphic/119617.html" rel="external">algorithm 1</a>). Choosing between these approaches is discussed separately. (See  <a class="medical medical_review" href="/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventing reaccumulation</strong> – At the time of or immediately after initial pericardial fluid removal, patients with suspected or confirmed malignant pericardial effusion should be treated with measures that reduce reaccumulation of pericardial effusion. (See <a class="local">'Prevention and treatment of recurrent malignant pericardial effusion'</a> below.)</p><p></p><p class="bulletIndent1">For those who have had pericardial fluid removal, the development of symptoms such as fatigue, dyspnea, or chest heaviness should prompt repeat echocardiography to assess for recurrent pericardial effusion. (See  <a class="medical medical_review" href="/d/html/4921.html" rel="external">"Cardiac tamponade"</a> and <a class="local">'Prevention and treatment of recurrent malignant pericardial effusion'</a> below and  <a class="medical medical_review" href="/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications of fluid removal</strong> – Pericardial fluid removal is generally tolerated. Rare complications of pericardiocentesis for cardiac tamponade include bleeding and heart failure (caused by posttap fluid shift into the central circulation). (See  <a class="medical medical_review" href="/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H3495819348"><span class="h1">PREVENTION AND TREATMENT OF RECURRENT MALIGNANT PERICARDIAL EFFUSION</span></p><p class="headingAnchor" id="H2748144872"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Patients with cardiac tamponade that is directly attributed to malignancy commonly reaccumulate pericardial fluid. Therefore, initial management with pericardial fluid removal is generally combined with or followed by one or more measures to prevent or treat recurrent malignant pericardial effusion, such as mechanical pericardial interventions (prolonged catheter drainage, repeated pericardiocentesis, surgical pericardiotomy, or, rarely, percutaneous balloon pericardiotomy) and cancer-directed systemic therapy. Selection of therapy by a multidisciplinary team (including a cardiologist, cardiac surgeon, and medical oncologist) is guided by the patient's overall clinical status (including symptoms, medical frailty, and comorbidities), prognosis, goals of care, care setting, and available treatment resources. Treatments should also focus on relieving symptoms, improving functional status, and minimizing repeat interventions.</p><p>The management of recurrent or chronic pericardial effusions in patients without cancer is discussed separately. (See  <a class="medical medical_review" href="/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis"</a>.)</p><p class="headingAnchor" id="H3812505373"><span class="h2">Mechanical pericardial interventions after initial pericardiocentesis</span></p><p class="headingAnchor" id="H1805975948"><span class="h3">Selection of intervention</span><span class="headingEndMark"> — </span>For patients with malignant pericardial effusion who are initially treated with fluid removal using pericardiocentesis, further mechanical cardiac interventions are generally necessary to treat or prevent pericardial fluid reaccumulation. Options include catheter drainage, surgical decompression of the pericardium, and, rarely, percutaneous balloon pericardiotomy.</p><p>For patients with malignant pericardial effusion, our approach to managing recurrent pericardial effusion is as follows [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial prevention and treatment of recurrent effusion</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For medically fit patients with longer life expectancy, a catheter designed for extended pericardial fluid drainage (typically three to five days) can be placed at the time of initial drainage with pericardiocentesis (for prevention) or at the time of pericardial fluid recurrence (for treatment), commonly with inpatient monitoring. (See <a class="local">'Extended catheter drainage'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with limited life expectancy and a recurrent malignant pericardial effusion may be offered repeat pericardiocentesis, particularly if this is the option most compatible with the chosen care setting (eg, home or hospice rather than a monitored setting). Best supportive care is an appropriate alternative for patients who are not candidates for repeat pericardiocentesis; this situation may occur due to procedural limitations (eg, pericardial fluid that is drained repeatedly may become more loculated and difficult to access percutaneously) or the inability of the patient to tolerate repeat procedures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory pericardial effusion</strong> – For those medically fit patients with recurrent or persistent malignant pericardial effusion who have undergone (or are expected to require) repeated pericardiocentesis or extended catheter drainage, surgical decompression of the pericardium is the standard approach (see <a class="local">'Surgical decompression of the pericardium'</a> below). We rarely use balloon pericardiotomy given its limitations, as discussed below (see <a class="local">'Balloon pericardiotomy'</a> below). The optimal treatment is not established since these approaches have not been directly compared in randomized trials.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid sclerosing agents</strong> – We do not use pericardial sclerosing agents, which are as effective as the other approaches in preventing pericardial effusion reaccumulation but commonly cause severe pain. (See <a class="local">'Avoidance of pericardial sclerosing agents'</a> below.)</p><p></p><p>Mechanical pericardial interventions are typically followed by systemic therapy directed at the specific cancer, as clinically indicated. (See <a class="local">'Cancer-directed therapy'</a> below.)</p><p>Although pericardiocentesis effectively relieves symptoms and improves hemodynamics, pericardial fluid reaccumulates in as many as 60 percent of patients [<a href="#rid2">2,3</a>]. As an example, one systematic review of 31 retrospective studies evaluated the effect of various percutaneous interventions on the recurrence rate of malignant pericardial effusion [<a href="#rid4">4</a>]. At follow-up ranging from two months to over one year, isolated pericardiocentesis demonstrated the highest rate of recurrent pericardial effusion (38 percent) relative to other mechanical interventions, including prolonged catheter drainage (12 percent), balloon pericardotomy (10 percent), and pericardial sclerosis (11 percent).</p><p class="headingAnchor" id="H994375321"><span class="h3">Extended catheter drainage</span><span class="headingEndMark"> — </span>For patients with malignant pericardial effusion, extended catheter drainage is an effective treatment option that reduces the risk of recurrent pericardial effusion to approximately 10 to 20 percent [<a href="#rid1">1,4-7</a>]. However, the duration of pericardial effusion control is variable and ranges approximately between 1 to 12 months in observational studies [<a href="#rid8">8,9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment approach</strong> – Catheter drainage is typically required for at least three to five days [<a href="#rid7">7,9</a>]. The catheter should not be removed until drainage is minimal (&lt;25 to 50 mL in a 24-hour period) to none. For patients who have had a catheter placed for three to five days whose rates of pericardial fluid drainage remains greater than 50 mL in a 24-hour period, we evaluate for a surgical pericardial window. (See <a class="local">'Surgical decompression of the pericardium'</a> below.)</p><p></p><p class="bulletIndent1">In one observational series of 171 patients with cancer and pericardial effusion who underwent echocardiography-guided pericardiocentesis followed by extended catheter drainage, the average time to minimal catheter output (&lt;50 mL in 24 hours) was three days [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – The reported incidence of complications from prolonged catheter drainage ranges from 7 to 17 percent [<a href="#rid10">10</a>]. Complications include pericarditic chest pain, catheter occlusion, infection, fever, pneumothorax, ventricular puncture, and cardiac arrest [<a href="#rid3">3,8,11</a>]. Intermittent rather than continuous drainage may help to maintain catheter patency and reduce risk for infection by decreasing the opportunity for retrograde migration of microbes or catheter tubing collapse that could cause occlusion.</p><p></p><p class="headingAnchor" id="H1481958971"><span class="h3">Surgical decompression of the pericardium</span><span class="headingEndMark"> — </span>Surgical decompression of the pericardium (via creation of a pericardial window) results in immediate hemodynamic benefit [<a href="#rid6">6,8,12-17</a>]. Surgical decompression is also associated with the lowest rates of recurrent pericardial effusion (0 to 7 percent) relative to other percutaneous interventions (ie, pericardiocentesis, catheter drainage, and balloon pericardotomy), but is the most invasive procedure. We prefer this approach in medically fit patients with recurrent or persistent malignant pericardial effusion who have undergone (or are expected to require) repeat pericardiocentesis or extended catheter drainage.</p><p>Surgical decompression of the pericardium has not been directly compared with other methods of pericardial drainage in randomized trials. In a systematic review of 59 observational studies, over a median follow-up of two months, surgical interventions were associated with better control of malignant pericardial effusion (93 to 100 percent) compared with percutaneous balloon pericardotomy (90 percent), single pericardiocentesis (67 percent), and extended catheter drainage (55 percent) [<a href="#rid10">10</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment approach</strong> – For patients with a hemodynamically significant pericardial effusion, we generally perform pericardiocentesis prior to surgery to avoid further hemodynamic instability or cardiovascular collapse during administration of general anesthesia prior to surgery [<a href="#rid17">17</a>]. However, some loculated pericardial effusions may require surgical drainage. (See  <a class="medical medical_review" href="/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Surgical creation of a pericardial window can be accomplished using various surgical techniques (eg, open surgery, video assisted thoracoscopy [VATS]). While recurrence rates vary slightly according to surgical technique, recurrence of a large or symptomatic pericardial effusion following transthoracic (thoracotomy or VATS) pericardiostomy was seen in only 5 to 10 percent of patients, compared with an approximately 20 percent rate following pericardiocentesis alone. Recurrence rates are slightly higher when a subxiphoid approach is used because these "windows" do not drain to an absorptive mesothelial surface [<a href="#rid17">17</a>]. Moreover, approximately one-third of patients with malignant pericardial disease have coexisting pleural pathology, which may need to be addressed concurrently.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – The frequency of postoperative complications for surgical decompression ranges from approximately 5 to 10 percent [<a href="#rid10">10</a>]. The most common complications include hemorrhage, infection, pulmonary embolism, arrythmias, and myocardial infarction.</p><p></p><p class="headingAnchor" id="H639463560"><span class="h3">Balloon pericardiotomy</span><span class="headingEndMark"> — </span>Due to its limitations, balloon pericardiotomy is a rarely used option to treat recurrent malignant pericardial effusion in patients previously treated with pericardiocentesis or catheter drainage. Balloon pericardiotomy causes pain and the size of the pericardial defect it creates is difficult to control, which increases the risk of early pericardial defect self-closure.</p><p>For patients treated with balloon pericardotomy, the recurrence rate for pericardial effusion ranges between 10 and 40 percent, with better outcomes seen in institutions with expertise in this procedure [<a href="#rid4">4,10,18-22</a>]. While there are no randomized trials comparing balloon pericardotomy with surgical decompression of the pericardium, observational data suggest that balloon pericardotomy is associated with lower rates of fluid recurrence (10 percent) relative to pericardiocentesis (38 percent) [<a href="#rid4">4</a>], but higher rates relative to surgical decompression (0 to 7 percent) [<a href="#rid10">10</a>]. (See <a class="local">'Surgical decompression of the pericardium'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment approach </strong>– Balloon pericardiotomy may be performed either immediately following initial pericardiocentesis or after pericardial effusion recurrence. Briefly, following catheter-based drainage, the pigtail catheter is exchanged over a wire for a larger balloon-tipped catheter that is inflated and extruded across the parietal pericardium to create a larger sized connection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications </strong>– Complications from balloon pericardotomy can occur in up to one-third of patients, including pneumothorax, pleural effusion, and infection [<a href="#rid10">10,18,21</a>]. Other, less common complications include hemorrhage and ventricular puncture.</p><p></p><p class="headingAnchor" id="H3082006657"><span class="h3">Avoidance of pericardial sclerosing agents</span><span class="headingEndMark"> — </span>We avoid the use of pericardial sclerosing agents due to significant toxicity. Pericardial sclerosing agents, such as <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, platinum-based chemotherapy, and <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> C, induce inflammation and fibrotic adhesion of the pericardial layers to reduce the potential space for fluid reaccumulation. Although pericardial sclerosis is associated with similar rates of recurrent pericardial effusion relative to other mechanical cardiac interventions, this approach is associated with severe chest pain and constrictive pericarditis and is no longer used [<a href="#rid4">4,23</a>].</p><p class="headingAnchor" id="H3197180218"><span class="h2">Cancer-directed therapy</span></p><p class="headingAnchor" id="H1751926688"><span class="h3">Systemic therapy</span><span class="headingEndMark"> — </span>Pericardial effusions and masses caused by cancer may respond to systemic antineoplastic therapy. This approach works best when combined with a mechanical method to promote pericardial drainage. In one observational study, systemic chemotherapy plus pericardial window was associated with a better treatment response (reduction in pericardial effusion or pericardial masses) compared with systemic chemotherapy plus pericardial drainage (92 versus 73 percent) [<a href="#rid24">24</a>]. Treatment with systemic chemotherapy alone was associated with the lowest response rate (54 percent).</p><p>The treatment of cancer types that are frequently associated with malignant pericardial effusions are discussed separately. (See  <a class="medical medical_review" href="/d/html/4954.html" rel="external">"Pericardial disease associated with cancer: Clinical presentation and diagnosis", section on 'Malignancy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung cancer</strong> – (See  <a class="medical medical_review" href="/d/html/4639.html" rel="external">"Overview of the initial treatment and prognosis of lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast cancer</strong> – (See  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Esophageal cancer</strong> – (See  <a class="medical medical_review" href="/d/html/2473.html" rel="external">"Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Melanoma</strong> – (See  <a class="medical medical_review" href="/d/html/85841.html" rel="external">"Overview of the management of advanced cutaneous melanoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute</strong> <strong>leukemia (AML and ALL)</strong> – (See  <a class="medical medical_review" href="/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/94786.html" rel="external">"Acute myeloid leukemia in adults: Overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hodgkin and non-Hodgkin</strong> <strong>lymphoma</strong> – (See  <a class="medical medical_review" href="/d/html/6246.html" rel="external">"Overview of Hodgkin lymphoma in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/13940.html" rel="external">"Overview of non-Hodgkin lymphoma in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults"</a> and  <a class="medical medical_review" href="/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H1694575274"><span class="h3">Other therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation therapy</strong> - Radiation therapy (RT) is used to treat radiosensitive cancers that may present adjacent to the heart, such as leukemias, lymphomas, lung, breast, and esophageal cancer. Multidisciplinary evaluation that includes the input of a radiation oncologist is necessary to manage patients who may benefit from the inclusion of radiation therapy and its sequencing with systemic therapy in this setting (eg, a patient with mediastinal lymphoma and pericardial effusion presumed to be caused by lymphatic obstruction). The decision on whether to include RT for patients with malignant pericardial effusion is based upon the potential benefits of cancer control and potential harms. These harms include acute side effects such as esophagitis and late toxicities such as pericardial, coronary, myocardial, and valve disease [<a href="#rid25">25-29</a>]. (See  <a class="medical medical_review" href="/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment", section on 'Radiation side effects'</a> and  <a class="medical medical_review" href="/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a> and  <a class="medical medical_review" href="/d/html/111731.html" rel="external">"Cardiotoxicity of radiation therapy for Hodgkin lymphoma and pediatric malignancies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intrapericardial chemotherap</strong>y – Intrapericardial chemotherapy is a less preferred treatment to treat malignant pericardial effusion [<a href="#rid25">25-29</a>] due to the availability of more effective systemic therapies for most advanced cancer that are more easily administered.</p><p></p><p class="headingAnchor" id="H1276901432"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Most patients with a symptomatic malignant pericardial effusion have a limited life expectancy (median two to four months), and many often develop recurrent pericardial effusion within this time [<a href="#rid3">3,8,12-14,16,21,30-34</a>]. Prognosis may be better in certain subsets of patients, such as those without malignant cells in the pericardium (at least in the setting of non-small cell lung cancer) [<a href="#rid35">35,36</a>], hematologic rather than solid tumors [<a href="#rid32">32</a>], breast cancer rather than some types of lung cancer [<a href="#rid5">5,32,37,38</a>], patients who are candidates for systemic therapy [<a href="#rid24">24,39</a>] or whose cancer is otherwise well-controlled with systemic therapy [<a href="#rid31">31</a>].</p><p>Many patients with cancer and pericardial disease will also benefit from palliative care services, which improves clinical outcomes and quality of life. (See  <a class="medical medical_review" href="/d/html/95552.html" rel="external">"Discussing goals of care"</a> and  <a class="medical medical_review" href="/d/html/14240.html" rel="external">"Benefits, services, and models of subspecialty palliative care"</a>.)</p><p class="headingAnchor" id="H2440711709"><span class="h1">PERICARDIAL EFFUSION WITHOUT CARDIAC TAMPONADE</span><span class="headingEndMark"> — </span>Asymptomatic or minimally symptomatic pericardial effusions without cardiac tamponade can be managed conservatively with careful clinical and echocardiographic monitoring and avoidance of volume depletion. Malignant pericardial effusions may also be treated with systemic antineoplastic therapy directed at the causative cancer type, if indicated (see <a class="local">'Cancer-directed therapy'</a> above). Some patients will never develop symptoms or require intervention, particularly patients with small pericardial effusions.</p><p>Pericardial fluid or tissue sampling is necessary to confirm the diagnosis of malignant pericardial effusion, which is discussed separately. (See  <a class="medical medical_review" href="/d/html/4954.html" rel="external">"Pericardial disease associated with cancer: Clinical presentation and diagnosis", section on 'Diagnosis of malignant pericardial disease'</a>.)</p><p>The development of symptoms such as fatigue, dyspnea, or chest heaviness should prompt evaluation, including assessment for cardiac tamponade with physical examination and echocardiography. (See  <a class="medical medical_review" href="/d/html/4954.html" rel="external">"Pericardial disease associated with cancer: Clinical presentation and diagnosis", section on 'Diagnostic evaluation for pericardial disease'</a>.)</p><p class="headingAnchor" id="H2978097117"><span class="h1">ACUTE PERICARDITIS</span><span class="headingEndMark"> — </span>For acute symptomatic pericarditis, the goals of therapy are relief of pain, resolution of inflammation (and, if present, pericardial effusion), and the prevention of recurrence. Because limited data are available to guide management of acute pericarditis specifically in cancer patients, most treatment recommendations are extrapolated from observational studies, indirect evidence in patients without cancer, and expert opinion.</p><p class="headingAnchor" id="H1322464948"><span class="h2">General approach</span><span class="headingEndMark"> — </span>Nearly all patients with acute pericarditis associated with cancer receive combination therapy with <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> plus nonsteroidal antiinflammatory drugs (NSAIDs)  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 1</a>). Our general approach to treatment of symptomatic acute pericarditis is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis"</a>.)</p><p>Pericarditis caused by cytotoxic cancer therapies often resolves with the above standard therapy or after discontinuation of the cytotoxic agent. In this setting, the potential risks and benefits of cancer treatment interruption should be evaluated by a multidisciplinary cardio-oncology team.</p><p>Glucocorticoid therapy is generally reserved for refractory cases (or those for whom NSAIDs are contraindicated)  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 1</a>). An exception is the treatment of patients with severe immune checkpoint inhibitor (ICI)-associated pericarditis, as discussed below. (See <a class="local">'Immune checkpoint inhibitor-associated pericarditis'</a> below.)</p><p class="headingAnchor" id="H2319066747"><span class="h2">Immune checkpoint inhibitor-associated pericarditis</span><span class="headingEndMark"> — </span>There are limited data to guide the management of ICI-associated pericarditis. Our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trivial or small effusion</strong> – Patients with mild ICI-associated pericarditis and trivial or small pericardial effusion may tolerate continuation of the ICI and are treated with standard combination therapy for acute pericarditis  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 1</a>) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate or large effusion</strong> – For patients with severe ICI-associated pericarditis with moderate or large pericardial effusion, management consists of discontinuing the ICI and treating with antiinflammatory agents. We suggest glucocorticoid therapy (eg, <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 1 mg/kg/day or <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 1 to 2 mg/kg/day) plus <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> (rather than an NSAID plus colchicine) [<a href="#rid40">40,41</a>]. This approach is based on observational data in ICI-associated pericarditis and indirect evidence in patients with refractory pericarditis associated with other causes (although the glucocorticoid dose is generally higher for ICI-associated pericarditis). (See  <a class="medical medical_review" href="/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Glucocorticoids'</a>.)</p><p></p><p class="bulletIndent1">Rarely, ICI-pericarditis may be refractory to initial glucocorticoid doses and <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>. Treatments that have been reported for refractory ICI-pericarditis include higher-dose glucocorticoid therapy (eg, <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 1 g/day) along with other immunosuppressive agents (eg, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid42">42</a>] or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> [<a href="#rid43">43</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac tamponade</strong> – Patients with ICI-associated pericarditis and cardiac tamponade also require drainage of the pericardial fluid. (See <a class="local">'Acute management of cardiac tamponade'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management after resolution</strong> – After symptoms and signs of acute pericarditis resolve, patients may be evaluated by a multidisciplinary team for possible reinitiation of the ICI with close monitoring for recurrent symptoms [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">The management of other cardiovascular toxicities related to ICI (including myocarditis) are discussed separately  (<a class="graphic graphic_table graphicRef116852" href="/d/graphic/116852.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Cardiovascular toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of other causes</strong> – Other causes of pericarditis (such as infection) should be evaluated and treated appropriately, as discussed separately. (See  <a class="medical medical_review" href="/d/html/2128.html" rel="external">"Purulent pericarditis"</a>.)</p><p></p><p class="headingAnchor" id="H50667184"><span class="h1">CONSTRICTIVE PERICARDITIS</span><span class="headingEndMark"> — </span>Constrictive pericardial disease directly due to malignancy is uncommon. Most cases of cancer-associated pericardial constriction fall into the effusive-constrictive category where the pericardial effusion is often the primary cause of symptoms and signs and initial therapy is generally drainage of the pericardial fluid. (See  <a class="medical medical_review" href="/d/html/140205.html" rel="external">"Constrictive pericarditis: Clinical features and causes", section on 'Incidence and causes'</a> and  <a class="medical medical_review" href="/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation", section on 'Effusive-constrictive pericarditis'</a>.)</p><p>Radiation therapy to the chest (primarily treatment for Hodgkin disease, breast cancer, or lung cancer) is one of the causes of constrictive pericarditis. Measures to reduce the risk of radiation-induced pericardial disease (and other cardiac toxicity affecting the coronary arteries, valves, and myocardium) include techniques for more precise targeting of radiotherapy, respiratory gating, and prone positioning for patients with breast cancer [<a href="#rid44">44</a>]. Some patients with radiation-induced constrictive pericarditis also have restrictive cardiomyopathy, which may also be caused by exposure to radiation. (See  <a class="medical medical_review" href="/d/html/140205.html" rel="external">"Constrictive pericarditis: Clinical features and causes", section on 'Constrictive pericarditis'</a> and  <a class="medical medical_review" href="/d/html/4954.html" rel="external">"Pericardial disease associated with cancer: Clinical presentation and diagnosis", section on 'Radiation'</a> and  <a class="medical medical_review" href="/d/html/4918.html" rel="external">"Restrictive cardiomyopathies"</a>.)</p><p>The rare patients with true malignant constrictive pericarditis may require surgical removal of the pericardium, if this intervention is justified by the overall prognosis. Pericardiectomy is the only definitive treatment option for patients with chronic constrictive pericarditis. Medical therapy (ie, diuretics) may be used as a temporizing measure and for patients who are not candidates for surgery. (See  <a class="medical medical_review" href="/d/html/140886.html" rel="external">"Constrictive pericarditis: Management and prognosis", section on 'Management of constrictive pericarditis'</a> and  <a class="medical medical_review" href="/d/html/4954.html" rel="external">"Pericardial disease associated with cancer: Clinical presentation and diagnosis"</a>.)</p><p class="headingAnchor" id="H4177505190"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116655.html" rel="external">"Society guideline links: Pericardial disease"</a>.)</p><p class="headingAnchor" id="H3156871443"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/3427.html" rel="external">"Patient education: Pericarditis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H37790459"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach</strong> – The management of pericardial disease in a patient with cancer is based upon multiple factors including symptoms, hemodynamic status, the type and etiology of pericardial disease, the type and stage of cancer, cancer prognosis, patient comorbidities, performance status, and goals of care. (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac tamponade</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Urgent drainage</strong> – Patients with cardiac tamponade require urgent drainage. For patients with cancer and cardiac tamponade, acute management is similar to that for nonmalignant cardiac tamponade, including supportive care with fluid repletion while preparing for urgent pericardial fluid removal (via pericardiocentesis or surgical pericardial window)  (<a class="graphic graphic_algorithm graphicRef119617" href="/d/graphic/119617.html" rel="external">algorithm 1</a>). Measures to reduce the risk of reaccumulation are instituted at the time of or immediately after initial pericardial fluid removal. (See <a class="local">'Acute management of cardiac tamponade'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial prevention and treatment of</strong> <strong>recurrent malignant pericardial effusion</strong> – For patients with malignant pericardial effusion with cardiac tamponade, initial management with pericardial fluid removal is usually combined with or followed by one or more measures to prevent or treat recurrent pericardial effusion. Options include mechanical pericardial interventions (repeated pericardiocentesis, prolonged catheter drainage or surgical pericardiotomy, or, rarely, percutaneous balloon pericardiotomy), cancer-directed systemic therapy, and palliative care. The choice of intervention is based upon factors including patient symptoms, medical frailty, prognosis, goals of therapy, comorbidities, and care setting. (See <a class="local">'Prevention and treatment of recurrent malignant pericardial effusion'</a> above and <a class="local">'Cancer-directed therapy'</a> above.)</p><p></p><p class="bulletIndent2">Patients treated with systemic antineoplastic therapy still require mechanical management for prevention and treatment of recurrent malignant effusion. (See <a class="local">'Cancer-directed therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory malignant pericardial effusion</strong> – For those medically fit patients with recurrent or persistent malignant pericardial effusion despite repeated pericardiocentesis or extended catheter drainage, we suggest surgical decompression of the pericardium rather than other pericardial interventions (such as balloon pericardiotomy or pericardial sclerosing agents) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Surgical decompression of the pericardium'</a> above.)</p><p></p><p class="bulletIndent2">For frail patients with limited life expectancy, alternative management strategies include repeated pericardiocentesis and palliative care measures. (See <a class="local">'Selection of intervention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pericardial effusion without cardiac tamponade</strong> – Pericardial effusions without cardiac tamponade can be managed with careful clinical and echocardiographic monitoring and avoidance of volume depletion. Malignant pericardial effusions may be treated with antineoplastic systemic agents, if indicated. (See <a class="local">'Pericardial effusion without cardiac tamponade'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute pericarditis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Non-ICI-associated pericarditis</strong> – For acute symptomatic pericarditis, the goals of therapy are relief of pain, resolution of inflammation (and, if present, pericardial effusion), and the prevention of recurrence. Nearly all patients with acute pericarditis associated with cancer not associated with immune checkpoint inhibitor (ICI) use are treated with combination therapy consisting of a nonsteroidal antiinflammatory drug (NSAID) plus <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 1</a>). (See <a class="local">'Acute pericarditis'</a> above and  <a class="medical medical_review" href="/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ICI-associated pericarditis</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with mild ICI-associated pericarditis may tolerate continuation of ICI and are treated with standard therapy for acute pericarditis  (<a class="graphic graphic_table graphicRef56484" href="/d/graphic/56484.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Medical therapies'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with severe ICI-associated pericarditis with moderate or large pericardial effusion, management consists of discontinuing the ICI and treating with antiinflammatory agents. We suggest treating with glucocorticoid therapy (eg, <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 1 mg/kg/day or <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 1 to 2 mg/kg/day) plus <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> rather than NSAID plus colchicine (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Constrictive pericarditis</strong> – The rare patients with true malignant constrictive pericarditis may require surgical removal of the pericardium, if this intervention is justified by the overall prognosis. Pericardiectomy is the only definitive treatment option for patients with chronic constrictive pericarditis. Diuretic therapy may be used as a temporizing measure and for patients who are not candidates for surgery. (See <a class="local">'Constrictive pericarditis'</a> above.)</p><p></p><p class="headingAnchor" id="H2556801843"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Howard (Jack) West, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schusler R, Meyerson SL. Pericardial Disease Associated with Malignancy. Curr Cardiol Rep 2018; 20:92.</a></li><li><a class="nounderline abstract_t">Laham RJ, Cohen DJ, Kuntz RE, et al. Pericardial effusion in patients with cancer: outcome with contemporary management strategies. Heart 1996; 75:67.</a></li><li><a class="nounderline abstract_t">Tsang TS, Seward JB, Barnes ME, et al. Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. Mayo Clin Proc 2000; 75:248.</a></li><li><a class="nounderline abstract_t">Virk SA, Chandrakumar D, Villanueva C, et al. Systematic review of percutaneous interventions for malignant pericardial effusion. Heart 2015; 101:1619.</a></li><li><a class="nounderline abstract_t">El Haddad D, Iliescu C, Yusuf SW, et al. Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion. J Am Coll Cardiol 2015; 66:1119.</a></li><li><a class="nounderline abstract_t">McDonald JM, Meyers BF, Guthrie TJ, et al. Comparison of open subxiphoid pericardial drainage with percutaneous catheter drainage for symptomatic pericardial effusion. Ann Thorac Surg 2003; 76:811.</a></li><li><a class="nounderline abstract_t">Lekhakul A, Assawakawintip C, Fenstad ER, et al. Safety and Outcome of Percutaneous Drainage of Pericardial Effusions in Patients with Cancer. Am J Cardiol 2018; 122:1091.</a></li><li><a class="nounderline abstract_t">Allen KB, Faber LP, Warren WH, Shaar CJ. Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. Ann Thorac Surg 1999; 67:437.</a></li><li><a class="nounderline abstract_t">Patel N, Rafique AM, Eshaghian S, et al. Retrospective comparison of outcomes, diagnostic value, and complications of percutaneous prolonged drainage versus surgical pericardiotomy of pericardial effusion associated with malignancy. Am J Cardiol 2013; 112:1235.</a></li><li><a class="nounderline abstract_t">Jama GM, Scarci M, Bowden J, Marciniak SJ. Palliative treatment for symptomatic malignant pericardial effusion†. Interact Cardiovasc Thorac Surg 2014; 19:1019.</a></li><li><a class="nounderline abstract_t">Celermajer DS, Boyer MJ, Bailey BP, Tattersall MH. Pericardiocentesis for symptomatic malignant pericardial effusion: a study of 36 patients. Med J Aust 1991; 154:19.</a></li><li><a class="nounderline abstract_t">Moores DW, Allen KB, Faber LP, et al. Subxiphoid pericardial drainage for pericardial tamponade. J Thorac Cardiovasc Surg 1995; 109:546.</a></li><li><a class="nounderline abstract_t">Cullinane CA, Paz IB, Smith D, et al. Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy. Chest 2004; 125:1328.</a></li><li><a class="nounderline abstract_t">Park JS, Rentschler R, Wilbur D. Surgical management of pericardial effusion in patients with malignancies. Comparison of subxiphoid window versus pericardiectomy. Cancer 1991; 67:76.</a></li><li><a class="nounderline abstract_t">Olson JE, Ryan MB, Blumenstock DA. Eleven years' experience with pericardial-peritoneal window in the management of malignant and benign pericardial effusions. Ann Surg Oncol 1995; 2:165.</a></li><li><a class="nounderline abstract_t">Hankins JR, Satterfield JR, Aisner J, et al. Pericardial window for malignant pericardial effusion. Ann Thorac Surg 1980; 30:465.</a></li><li><a class="nounderline abstract_t">DeCamp MM Jr, Mentzer SJ, Swanson SJ, Sugarbaker DJ. Malignant effusive disease of the pleura and pericardium. Chest 1997; 112:291S.</a></li><li><a class="nounderline abstract_t">Wang HJ, Hsu KL, Chiang FT, et al. Technical and prognostic outcomes of double-balloon pericardiotomy for large malignancy-related pericardial effusions. Chest 2002; 122:893.</a></li><li><a class="nounderline abstract_t">Galli M, Politi A, Pedretti F, et al. Percutaneous balloon pericardiotomy for malignant pericardial tamponade. Chest 1995; 108:1499.</a></li><li><a class="nounderline abstract_t">Jalisi FM, Morise AP, Haque R, Jain AC. Primary percutaneous balloon pericardiotomy. W V Med J 2004; 100:102.</a></li><li><a class="nounderline abstract_t">Ziskind AA, Pearce AC, Lemmon CC, et al. Percutaneous balloon pericardiotomy for the treatment of cardiac tamponade and large pericardial effusions: description of technique and report of the first 50 cases. J Am Coll Cardiol 1993; 21:1.</a></li><li><a class="nounderline abstract_t">Swanson N, Mirza I, Wijesinghe N, Devlin G. Primary percutaneous balloon pericardiotomy for malignant pericardial effusion. Catheter Cardiovasc Interv 2008; 71:504.</a></li><li><a class="nounderline abstract_t">Lin MT, Yang PC, Luh KT. Constrictive pericarditis after sclerosing therapy with mitomycin C for malignant pericardial effusion: report of a case. J Formos Med Assoc 1994; 93:250.</a></li><li><a class="nounderline abstract_t">Çelik S, Lestuzzi C, Cervesato E, et al. Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions. J Thorac Cardiovasc Surg 2014; 148:2288.</a></li><li><a class="nounderline abstract_t">Imai H, Kaira K, Masubuchi K, Minato K. Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study. Curr Oncol 2021; 29:163.</a></li><li><a class="nounderline abstract_t">Maisch B, Ristić AD, Pankuweit S, et al. Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J 2002; 23:1625.</a></li><li><a class="nounderline abstract_t">Lestuzzi C, Bearz A, Lafaras C, et al. Neoplastic pericardial disease in lung cancer: impact on outcomes of different treatment strategies. A multicenter study. Lung Cancer 2011; 72:340.</a></li><li><a class="nounderline abstract_t">Bishiniotis TS, Antoniadou S, Katseas G, et al. Malignant cardiac tamponade in women with breast cancer treated by pericardiocentesis and intrapericardial administration of triethylenethiophosphoramide (thiotepa). Am J Cardiol 2000; 86:362.</a></li><li><a class="nounderline abstract_t">Kotake M, Imai H, Kaira K, et al. Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study. Cancer Chemother Pharmacol 2019; 84:655.</a></li><li><a class="nounderline abstract_t">Gross JL, Younes RN, Deheinzelin D, et al. Surgical management of symptomatic pericardial effusion in patients with solid malignancies. Ann Surg Oncol 2006; 13:1732.</a></li><li><a class="nounderline abstract_t">Dequanter D, Lothaire P, Berghmans T, Sculier JP. Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival. Ann Surg Oncol 2008; 15:3268.</a></li><li><a class="nounderline abstract_t">Dosios T, Theakos N, Angouras D, Asimacopoulos P. Risk factors affecting the survival of patients with pericardial effusion submitted to subxiphoid pericardiostomy. Chest 2003; 124:242.</a></li><li><a class="nounderline abstract_t">Maher EA, Shepherd FA, Todd TJ. Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg 1996; 112:637.</a></li><li><a class="nounderline abstract_t">Piehler JM, Pluth JR, Schaff HV, et al. Surgical management of effusive pericardial disease. Influence of extent of pericardial resection on clinical course. J Thorac Cardiovasc Surg 1985; 90:506.</a></li><li><a class="nounderline abstract_t">Neragi-Miandoab S, Linden PA, Ducko CT, et al. VATS pericardiotomy for patients with known malignancy and pericardial effusion: survival and prognosis of positive cytology and metastatic involvement of the pericardium: a case control study. Int J Surg 2008; 6:110.</a></li><li><a class="nounderline abstract_t">Wang PC, Yang KY, Chao JY, et al. Prognostic role of pericardial fluid cytology in cardiac tamponade associated with non-small cell lung cancer. Chest 2000; 118:744.</a></li><li><a class="nounderline abstract_t">Girardi LN, Ginsberg RJ, Burt ME. Pericardiocentesis and intrapericardial sclerosis: effective therapy for malignant pericardial effusions. Ann Thorac Surg 1997; 64:1422.</a></li><li><a class="nounderline abstract_t">García-Riego A, Cuiñas C, Vilanova JJ. Malignant pericardial effusion. Acta Cytol 2001; 45:561.</a></li><li><a class="nounderline abstract_t">Hu ZG, Hu K, Li WX, Zeng FJ. Prognostic factors and nomogram for cancer-specific death in non small cell lung cancer with malignant pericardial effusion. PLoS One 2019; 14:e0217007.</a></li><li><a class="nounderline abstract_t">Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43:4229.</a></li><li><a class="nounderline abstract_t">Cozma A, Sporis ND, Lazar AL, et al. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Int J Mol Sci 2022; 23.</a></li><li><a class="nounderline abstract_t">Moriyama S, Fukata M, Tatsumoto R, Kono M. Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report. Eur Heart J Case Rep 2021; 5:ytab002.</a></li><li><a class="nounderline abstract_t">Verhaert M, Mebis J, Aspeslagh S, von Kemp B. Steroid-dependent pericarditis following anti-PD1 immunotherapy in a metastatic melanoma patient: a case report. Eur Heart J Case Rep 2023; 7:ytad112.</a></li><li><a class="nounderline abstract_t">Szpakowski N, Desai MY. Radiation-Associated Pericardial Disease. Curr Cardiol Rep 2019; 21:97.</a></li></ol></div><div id="topicVersionRevision">Topic 141940 Version 2.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30128844" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pericardial Disease Associated with Malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8624876" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pericardial effusion in patients with cancer: outcome with contemporary management strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10725950" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26180077" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Systematic review of percutaneous interventions for malignant pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26337990" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12963206" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Comparison of open subxiphoid pericardial drainage with percutaneous catheter drainage for symptomatic pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30064854" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Safety and Outcome of Percutaneous Drainage of Pericardial Effusions in Patients with Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10197666" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23827405" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Retrospective comparison of outcomes, diagnostic value, and complications of percutaneous prolonged drainage versus surgical pericardiotomy of pericardial effusion associated with malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25142067" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Palliative treatment for symptomatic malignant pericardial effusion†.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1701847" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pericardiocentesis for symptomatic malignant pericardial effusion: a study of 36 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7877317" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Subxiphoid pericardial drainage for pericardial tamponade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15078742" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1702345" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Surgical management of pericardial effusion in patients with malignancies. Comparison of subxiphoid window versus pericardiectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7728571" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Eleven years' experience with pericardial-peritoneal window in the management of malignant and benign pericardial effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7436617" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pericardial window for malignant pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9337306" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Malignant effusive disease of the pleura and pericardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12226029" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Technical and prognostic outcomes of double-balloon pericardiotomy for large malignancy-related pericardial effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7497750" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Percutaneous balloon pericardiotomy for malignant pericardial tamponade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15384742" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Primary percutaneous balloon pericardiotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8417048" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Percutaneous balloon pericardiotomy for the treatment of cardiac tamponade and large pericardial effusions: description of technique and report of the first 50 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18307242" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Primary percutaneous balloon pericardiotomy for malignant pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7920067" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Constrictive pericarditis after sclerosing therapy with mitomycin C for malignant pericardial effusion: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24836991" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35049689" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12323163" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21122938" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Neoplastic pericardial disease in lung cancer: impact on outcomes of different treatment strategies. A multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10922456" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Malignant cardiac tamponade in women with breast cancer treated by pericardiocentesis and intrapericardial administration of triethylenethiophosphoramide (thiotepa).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31250155" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17028771" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Surgical management of symptomatic pericardial effusion in patients with solid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18648881" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12853529" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risk factors affecting the survival of patients with pericardial effusion submitted to subxiphoid pericardiostomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8800150" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4046619" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Surgical management of effusive pericardial disease. Influence of extent of pericardial resection on clinical course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18329349" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : VATS pericardiotomy for patients with known malignancy and pericardial effusion: survival and prognosis of positive cytology and metastatic involvement of the pericardium: a case control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10988197" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prognostic role of pericardial fluid cytology in cardiac tamponade associated with non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9386714" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pericardiocentesis and intrapericardial sclerosis: effective therapy for malignant pericardial effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11480719" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Malignant pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31095610" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prognostic factors and nomogram for cancer-specific death in non small cell lung cancer with malignant pericardial effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36017568" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36142866" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33644656" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36937234" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Steroid-dependent pericarditis following anti-PD1 immunotherapy in a metastatic melanoma patient: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31352541" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Radiation-Associated Pericardial Disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
